Orkun Ilgen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Orkun Ilgen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Sefa Kurt
Faculty of Medicine, Department of Obstetrics and Gynecology Dokuz Eylul University Izmir Turkey
6 shared publications - Volkan Karataşlı
Department of Obstetrics and Gynecology, Balikesir Ataturk City Hospital, Balikesir 10100, Turkey
4 shared publications - Filiz Yilmaz
Faculty of Medicine, Department of Histology and Embryology Hitit University Corum Turkey
3 shared publications Sefa Kurt
Eylul University School of Medicine Department of Obstetrics and Gynecology, Izmir, Turkey
3 shared publications- Begum Ertan
Department of Gynecology and Obstetrics, Saglik Bakanligi Akhisar Mustafa Kirazoglu Devlet Hastanesi
2 shared publications Hakan Kula
Dokuz Eylul University School of Medicine Department of Obstetrics and Gynecology, Izmir, Türkiye
2 shared publications
Latest Publications
- 3 June 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (6) , e70355
The Effect of Hesperidin in a Rat Uterine Scar Model: A Biochemical and Histological Study
Background: We aimed to evaluate whether hesperidin has a therapeutic role in a uterine scar model created by performing a full‐thickness incision on the rat uterus. Materials: Twenty‐eight female Wistar albino rats were divided into four groups. A uterine scar model was created in the scar groups, and hesperidin was administered to the hesperidin groups for 30 days. Four rats from each group were sacrificed, left horns were used for histopathological evaluation (H&E, Masson, TGF‐Beta, alpha‐SMA), and the right horns were used for biochemical assessment (MDA, SOD, GSH). The remaining rats were mated and subjected to a fertility test. Results: In the histopathological evaluation, similar findings were observed in the control and hesperidin groups. Compared with the scar group, the treatment group showed reduced inflammation, decreased collagen deposition, and increased angiogenesis ( p < 0.05). Collagen accumulation detected by Masson staining was highest in the scar group, and the highest alpha‐SMA immunostaining score was also observed in the scar group. In the biochemical analysis, the treatment group exhibited lower MDA levels and higher SOD and GSH levels compared with the scar group. In the fertility test, the lowest pregnancy rate was found in the scar group, while the other groups showed similar averages. Conclusions: Our study demonstrated that hesperidin may prevent uterine scar formation and contribute to the management of postoperative complications. The hesperidin reflected antifibrotic effects and the prevention of collagen accumulation. Additionally, this study is the first in the literature to investigate the in vivo effects of hesperidin on uterine scar formation.
- 3 June 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (6) , e70355
The Effect of Hesperidin in a Rat Uterine Scar Model: A Biochemical and Histological Study
Background: We aimed to evaluate whether hesperidin has a therapeutic role in a uterine scar model created by performing a full‐thickness incision on the rat uterus. Materials: Twenty‐eight female Wistar albino rats were divided into four groups. A uterine scar model was created in the scar groups, and hesperidin was administered to the hesperidin groups for 30 days. Four rats from each group were sacrificed, left horns were used for histopathological evaluation (H&E, Masson, TGF‐Beta, alpha‐SMA), and the right horns were used for biochemical assessment (MDA, SOD, GSH). The remaining rats were mated and subjected to a fertility test. Results: In the histopathological evaluation, similar findings were observed in the control and hesperidin groups. Compared with the scar group, the treatment group showed reduced inflammation, decreased collagen deposition, and increased angiogenesis ( p < 0.05). Collagen accumulation detected by Masson staining was highest in the scar group, and the highest alpha‐SMA immunostaining score was also observed in the scar group. In the biochemical analysis, the treatment group exhibited lower MDA levels and higher SOD and GSH levels compared with the scar group. In the fertility test, the lowest pregnancy rate was found in the scar group, while the other groups showed similar averages. Conclusions: Our study demonstrated that hesperidin may prevent uterine scar formation and contribute to the management of postoperative complications. The hesperidin reflected antifibrotic effects and the prevention of collagen accumulation. Additionally, this study is the first in the literature to investigate the in vivo effects of hesperidin on uterine scar formation.
- 25 April 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (8) , 104724
V-NOTES radical hysterectomy in cervical carcinoma: case report
- 25 April 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (8) , 104724
V-NOTES radical hysterectomy in cervical carcinoma: case report
- Open Access
- 8 March 2026
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 97 (3) , 212-217
The relationship of the umbilical artery half peak systolic velocity deceleration time with postpartum APGAR scores and umbilical cord blood pH in pregnancy with fetal growth restriction
Objectives: This study aims to examine the correlation between neonatal reactions and umbilical artery half peak systolic velocity deceleration time (UA HPSVDT). Material and methods: For the research, participants were selected among 24–40 weeks pregnant women. While the study group consisted of those with fetal growth restriction (FGR), the control group included the rest. To determine UA HPSVDT and certain doppler parameters, Doppler ultrasonography was used and within a week before delivery, the middle cerebral artery (MCA doppler was obtained). Likewise, a peri-operatively taken blood sample made it possible to determine Cord blood pH. APGAR scores of neonates were assessed within the 1–5th minutes. Results: In terms of fetal weight, cord blood pH, 1st and 5th minute APGAR scores and UA HPSVDT (for all parameters p < 0.01), a significant statistical difference was found between FGR and control groups. On the other hand, a significant correlation among neonatal weight, cord blood pH, 1–5th minute APGAR scores and UA HPSVDT were observed. It was clear that in the FGR group (for all parameters p < 0.01), the APGAR scores, cord blood pH, and neonatal weight decreased as the UA HPSVDT decreased. However, between UA HPSVDT and other variables, no remarkable statistical significance was determined. Conclusions: The research makes it clear that the UA HPSVDT time is related to umbilical artery of blood pH levels and post-natal APGAR scores; therefore, it can be useful for efforts to minimize the rate of mortality and morbidity in perinatal practices. Keywords: fetal growth restriction umbilical artery doppler umbilical artery half peak systolic velocity deceleration time
- 8 March 2026
- Published by VM Media Group sp. z o.o in Ginekologia Polska
- Vol. 97 (3) , 212-217
Open AccessThe relationship of the umbilical artery half peak systolic velocity deceleration time with postpartum APGAR scores and umbilical cord blood pH in pregnancy with fetal growth restriction
Objectives: This study aims to examine the correlation between neonatal reactions and umbilical artery half peak systolic velocity deceleration time (UA HPSVDT). Material and methods: For the research, participants were selected among 24–40 weeks pregnant women. While the study group consisted of those with fetal growth restriction (FGR), the control group included the rest. To determine UA HPSVDT and certain doppler parameters, Doppler ultrasonography was used and within a week before delivery, the middle cerebral artery (MCA doppler was obtained). Likewise, a peri-operatively taken blood sample made it possible to determine Cord blood pH. APGAR scores of neonates were assessed within the 1–5th minutes. Results: In terms of fetal weight, cord blood pH, 1st and 5th minute APGAR scores and UA HPSVDT (for all parameters p < 0.01), a significant statistical difference was found between FGR and control groups. On the other hand, a significant correlation among neonatal weight, cord blood pH, 1–5th minute APGAR scores and UA HPSVDT were observed. It was clear that in the FGR group (for all parameters p < 0.01), the APGAR scores, cord blood pH, and neonatal weight decreased as the UA HPSVDT decreased. However, between UA HPSVDT and other variables, no remarkable statistical significance was determined. Conclusions: The research makes it clear that the UA HPSVDT time is related to umbilical artery of blood pH levels and post-natal APGAR scores; therefore, it can be useful for efforts to minimize the rate of mortality and morbidity in perinatal practices. Keywords: fetal growth restriction umbilical artery doppler umbilical artery half peak systolic velocity deceleration time
- 19 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (6) , 104610
Vaginal natural orifice transluminal endoscopic surgery pelvic and para-aortic lymphadenectomy in endometrial cancer: a case report
- 19 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (6) , 104610
Vaginal natural orifice transluminal endoscopic surgery pelvic and para-aortic lymphadenectomy in endometrial cancer: a case report
- 1 October 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (10) , e70088
Histological, Immunohistochemical, and Biochemical Evaluation of the Effect of Berberine on Ovarian Hyperstimulation Syndrome in Rats
Aim: OHSS is a potentially fatal condition. We aimed to investigate the effects of berberine administration on folliculogenesis and VEGF, TGF‐α, IL‐1β, and IL‐6 levels in the OHSS model. Method: A total of 28 female immature Wistar albino rats were divided into four groups: Sham group, Berberine group, OHSS group, and OHSS + Bb group. An OHSS model was created in which 10 IU PMSG was administered for four consecutive days and 30 IU hCG on Day 5. On Day 7, all subjects were sacrificed. Body weight, ovarian weight, histologic evaluation of ovaries, biochemical evaluation of TGF‐α, IL‐1β, and IL‐6 expressions, and VEGF immunohistochemical analysis were performed. Results: Body weight, ovarian weight, follicular cell degeneration, vascular congestion, edema, and inflammation parameters were highest in the OHSS group ( p < 0.05). In the OHSS + Bb group, primary follicles and secondary follicles increased, while corpus luteum, atretic follicles, TGF‐α, IL‐1β, and IL‐6 levels, and VEGF expressions decreased compared to the OHSS group ( p < 0.05). No statistical difference was observed between the control group and the OHSS + Bb group. Conclusion: In the present study, we demonstrated that berberine has the potential to prevent the development of OHSS in animal models. This finding suggests that further investigation into the use of berberine in human studies could provide valuable insights and inform the development of effective treatment strategies for OHSS. Consequently, the risk of OHSS can be reduced by administering berberine to patients undergoing the controlled ovarian hyperstimulation protocol. Therefore, the life risk of patients due to OHSS may be eliminated.
- 1 October 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (10) , e70088
Histological, Immunohistochemical, and Biochemical Evaluation of the Effect of Berberine on Ovarian Hyperstimulation Syndrome in Rats
Aim: OHSS is a potentially fatal condition. We aimed to investigate the effects of berberine administration on folliculogenesis and VEGF, TGF‐α, IL‐1β, and IL‐6 levels in the OHSS model. Method: A total of 28 female immature Wistar albino rats were divided into four groups: Sham group, Berberine group, OHSS group, and OHSS + Bb group. An OHSS model was created in which 10 IU PMSG was administered for four consecutive days and 30 IU hCG on Day 5. On Day 7, all subjects were sacrificed. Body weight, ovarian weight, histologic evaluation of ovaries, biochemical evaluation of TGF‐α, IL‐1β, and IL‐6 expressions, and VEGF immunohistochemical analysis were performed. Results: Body weight, ovarian weight, follicular cell degeneration, vascular congestion, edema, and inflammation parameters were highest in the OHSS group ( p < 0.05). In the OHSS + Bb group, primary follicles and secondary follicles increased, while corpus luteum, atretic follicles, TGF‐α, IL‐1β, and IL‐6 levels, and VEGF expressions decreased compared to the OHSS group ( p < 0.05). No statistical difference was observed between the control group and the OHSS + Bb group. Conclusion: In the present study, we demonstrated that berberine has the potential to prevent the development of OHSS in animal models. This finding suggests that further investigation into the use of berberine in human studies could provide valuable insights and inform the development of effective treatment strategies for OHSS. Consequently, the risk of OHSS can be reduced by administering berberine to patients undergoing the controlled ovarian hyperstimulation protocol. Therefore, the life risk of patients due to OHSS may be eliminated.
- Open Access
- 1 June 2024
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 51 (2) , 112-119
Patterns of proliferation and fibrosis in a rat model of endometriosis following administration of Allium cepa
Objective: Endometriosis is a common gynecological disease among reproductive-age women. Numerous hypotheses exist regarding the pathogenesis of endometriosis. In Turkey, the consumption of Allium cepa (commonly known as the “onion cure”) is a popular treatment employed to alleviate a variety of gynecological disorders. Methods: In this study, our objective was to assess the therapeutic mechanisms of the onion bulb A. cepa using an autologous endometriosis model in Sprague-Dawley rats. Previous research has shown that A. cepa possesses anti-inflammatory, antioxidant, and antiapoptotic properties. We evaluated the pathological condition of endometriotic implants by employing hematoxylin-eosin staining and Ki67 immunohistochemistry analysis. Transforming growth factor-beta 1 (TGF-β1) and alpha-smooth muscle actin (α-SMA) have been identified as profibrotic markers that are highly overexpressed in endometriotic tissues relative to eutopic endometrial tissue. Furthermore, TGF-β1 influences the differentiation and progression of endometriosis. To quantify profibrotic activity, we measured TGF-β1 and α-SMA using the immunosorbent assay method.Results: Lower histologic evaluation scores for endometriotic implants were observed in the group receiving high-dose A. cepa relative to the other groups. Ki67 expression was reduced following the high-dose A. cepa regimen, which consisted of 30% A. cepa and 70% normal feed. However, no statistically significant differences in TGF-β1 or α-SMA levels were observed among the groups (p=0.7 and p=0.778, respectively). Conclusion: The findings suggest that A. cepa could serve as a therapeutic agent in endometriosis treatment, as evidenced by the reduction in proliferative potential. Nevertheless, A. cepa was not associated with significantly lower levels of endometriosis-associated TGF-β1 or α-SMA.
- 1 June 2024
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 51 (2) , 112-119
Open AccessPatterns of proliferation and fibrosis in a rat model of endometriosis following administration of Allium cepa
Objective: Endometriosis is a common gynecological disease among reproductive-age women. Numerous hypotheses exist regarding the pathogenesis of endometriosis. In Turkey, the consumption of Allium cepa (commonly known as the “onion cure”) is a popular treatment employed to alleviate a variety of gynecological disorders. Methods: In this study, our objective was to assess the therapeutic mechanisms of the onion bulb A. cepa using an autologous endometriosis model in Sprague-Dawley rats. Previous research has shown that A. cepa possesses anti-inflammatory, antioxidant, and antiapoptotic properties. We evaluated the pathological condition of endometriotic implants by employing hematoxylin-eosin staining and Ki67 immunohistochemistry analysis. Transforming growth factor-beta 1 (TGF-β1) and alpha-smooth muscle actin (α-SMA) have been identified as profibrotic markers that are highly overexpressed in endometriotic tissues relative to eutopic endometrial tissue. Furthermore, TGF-β1 influences the differentiation and progression of endometriosis. To quantify profibrotic activity, we measured TGF-β1 and α-SMA using the immunosorbent assay method.Results: Lower histologic evaluation scores for endometriotic implants were observed in the group receiving high-dose A. cepa relative to the other groups. Ki67 expression was reduced following the high-dose A. cepa regimen, which consisted of 30% A. cepa and 70% normal feed. However, no statistically significant differences in TGF-β1 or α-SMA levels were observed among the groups (p=0.7 and p=0.778, respectively). Conclusion: The findings suggest that A. cepa could serve as a therapeutic agent in endometriosis treatment, as evidenced by the reduction in proliferative potential. Nevertheless, A. cepa was not associated with significantly lower levels of endometriosis-associated TGF-β1 or α-SMA.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 57, e009062024
A rare complication of brucellosis: Superinfection of a mature ovarian cystic teratoma
A 43-year-old woman rural dweller working in animal husbandry presented with high fever, chills, nausea, and vomiting. She was diagnosed with brucellosis based on the Brucella standard tube agglutination test and blood culture results. Due to persistent vomiting, she was treated with intravenous tigecycline and oral gentamicin and rifampicin therapy. However, despite appropriate antimicrobial treatment, a clinical and laboratory response was not achieved. The course of inflammation indicators during treatment is shown in Figure 1. Right lower quadrant tenderness was noted on abdominal examination. Magnetic resonance imaging revealed a 12-cm cyst in the region of the right ovary, which was suspected to be a mature cystic teratoma ( Figure 2). We performed right ovariectomy and cystectomy ( Figure 3). The patient’s fever, nausea, and vomiting resolved from postoperative day 2. İntraoperative cultures of samples of the teratoma yielded Brucella spp. The patient's treatment was switched to rifampicin and doxycycline 2 weeks postoperatively and was discontinued after 8 weeks. Treatment failure in brucellosis is defined as the persistence of disease signs and/or symptoms after the initiation of appropriate antimicrobial therapy1 1. Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One. 2012;7(2) e32090. . The most common complications of brucellosis are osteoarticular and genitourinary involvement2 2. Ozger HS, Karasahin O, Yildiz Y and Dizbay M. Osteoarticular Involvement and Inadequate Treatment of Brucellosis are Related to Relapse. Mediterranean Journal of Infection, Microbes & Antimicrobials. 2020;9(1):NA- NA . Considering the potential of Brucella to invade several tissues, this case illustrates the importance of genitourinary system evaluation in the event of treatment failure3 3. Uwaydah M, Khalil A, Shamsuddine N, Matar F and Araj G. Brucella-infected ovarian dermoid cyst causing initial treatment failure in a patient with acute brucellosis. Infection 1998; 26: 131-132. . Furthermore, tigecycline may be an option for combination therapy in patients with severe brucellosis4 4. Dizbay M, Kilic S, Hizel K and Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis. 2007; 39 (5): 432-434. .
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 57, e009062024
Open AccessA rare complication of brucellosis: Superinfection of a mature ovarian cystic teratoma
A 43-year-old woman rural dweller working in animal husbandry presented with high fever, chills, nausea, and vomiting. She was diagnosed with brucellosis based on the Brucella standard tube agglutination test and blood culture results. Due to persistent vomiting, she was treated with intravenous tigecycline and oral gentamicin and rifampicin therapy. However, despite appropriate antimicrobial treatment, a clinical and laboratory response was not achieved. The course of inflammation indicators during treatment is shown in Figure 1. Right lower quadrant tenderness was noted on abdominal examination. Magnetic resonance imaging revealed a 12-cm cyst in the region of the right ovary, which was suspected to be a mature cystic teratoma ( Figure 2). We performed right ovariectomy and cystectomy ( Figure 3). The patient’s fever, nausea, and vomiting resolved from postoperative day 2. İntraoperative cultures of samples of the teratoma yielded Brucella spp. The patient's treatment was switched to rifampicin and doxycycline 2 weeks postoperatively and was discontinued after 8 weeks. Treatment failure in brucellosis is defined as the persistence of disease signs and/or symptoms after the initiation of appropriate antimicrobial therapy1 1. Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One. 2012;7(2) e32090. . The most common complications of brucellosis are osteoarticular and genitourinary involvement2 2. Ozger HS, Karasahin O, Yildiz Y and Dizbay M. Osteoarticular Involvement and Inadequate Treatment of Brucellosis are Related to Relapse. Mediterranean Journal of Infection, Microbes & Antimicrobials. 2020;9(1):NA- NA . Considering the potential of Brucella to invade several tissues, this case illustrates the importance of genitourinary system evaluation in the event of treatment failure3 3. Uwaydah M, Khalil A, Shamsuddine N, Matar F and Araj G. Brucella-infected ovarian dermoid cyst causing initial treatment failure in a patient with acute brucellosis. Infection 1998; 26: 131-132. . Furthermore, tigecycline may be an option for combination therapy in patients with severe brucellosis4 4. Dizbay M, Kilic S, Hizel K and Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis. 2007; 39 (5): 432-434. .
- Open Access
- 1 December 2023
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 7 (12) , 754-759
Endometrial pathologies in clinical follow-up of patients with hormone receptor-positive/negative breast cancer
Background/Aim: Breast cancer is the leading cause of cancer-related fatalities in women. Tamoxifen, a selective estrogen receptor modulator (SERM), is frequently employed for chemoprevention in hormone receptor (HR)-positive breast cancer patients due to its anti-estrogenic impact on breast tissue. Nevertheless, tamoxifen exhibits agonistic effects on the endometrium, particularly in postmenopausal women. This study aims to assess gynecological issues and endometrial pathologies that emerge during the treatment and follow-up phases of women diagnosed with HR-positive/negative breast cancer. Methods: This cohort study involved a data review from 857 breast cancer patients diagnosed over a decade at a tertiary center. Histopathological endometrial findings were evaluated for 166 patients who underwent gynecological consultations before breast cancer treatment with normal examination results and underwent invasive assessments due to gynecological symptoms that arose during treatment and follow-up. The study encompassed cases culminating in total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH+BSO). Results: The study analyzed 166 cases meeting the inclusion criteria. The mean age at breast cancer diagnosis was 48 years with a standard deviation of 8.4 years, and the average follow-up duration was 4.1 (3.8) years. The predominant histopathological type was invasive ductal carcinoma (75.3%). Of the cases, 68.6% occurred during premenopausal and 31.4% during postmenopause. HR positivity was identified in 136 cases (81.9%), while 30 (18.1%) exhibited negative HR status. Among HR-positive cases, 113 (83.0%) received tamoxifen treatment, while 23 (17.0%) were treated with letrozole. Common clinical findings during and after treatment encompassed increased endometrial thickness (ET) and abnormal uterine bleeding (AUB). Histopathological evaluation of invasive procedures prompted by increased ET indicated the following frequent endometrial findings: proliferative endometrium (33.1%), endometrial polyp (20.5%), and endometrial hyperplasia (EH) without atypia (9%). The histopathological outcomes of invasive procedures prompted by AUB included atrophic endometrium (11.4%), proliferative endometrium (3.6%), and endometrial cancer (1.8%). Among the endometrial malignancies, three occurred in the premenopausal phase and four in the postmenopausal phase. Notably, three of the seven endometrial malignancies were observed in the tamoxifen hormone therapy group, all HR-positive. Four cases were from the non-tamoxifen hormone therapy group with negative HR status. Conclusion: Globally, breast cancer ranks as the most prevalent malignancy in women. Tamoxifen, a frequently utilized adjuvant therapy post breast cancer surgery, can exert diverse effects on gynecological organs, encompassing benign pathologies like increased ET and malignant pathologies like uterine neoplasia. There is a rising suspicion that etiopathogenetic factors contributing to breast cancer progression might also precipitate uterine cancer, irrespective of tamoxifen use. Vigilant patient monitoring is paramount for detecting uterine neoplasia and other gynecological pathologies. '+st+' Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May 4;71(3):209–49. Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012 Apr 26;344(apr26 1):e2718–e2718. Jordan VC. The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Ann Surg Oncol. 2019 Jul 25;26(7):1981–90. Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020 Sep 7;12(9):2535. Fleming CA, Heneghan HM, O’Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. British Journal of Surgery. 2018 Jul 11;105(9):1098–106. Freeman EW, Sammel MD, Gracia CR, Kapoor S, Lin H, Liu L, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril. 2005 Feb;83(2):383–92. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022 Nov 3;72(6):524–41. Yin L, Duan JJ, Bian XW, Yu S cang. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research. 2020 Dec 9;22(1):61. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of Endometrial Changes among Symptomatic Tamoxifen-Treated and Nontreated Premenopausal and Postmenopausal Breast Cancer Patients. Gynecol Oncol. 1997 Aug;66(2):233–7. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJD, Cordoba M, et al. Time-Dependent Effect of Tamoxifen Therapy on Endometrial Pathology in Asymptomatic Postmenopausal Breast Cancer Patients. International Journal of Gynecological Pathology. 1996 Apr;15(2):152–7. Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, et al. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-535.e5. Şahin Uysal N, Boyraz G, Usubütün A, Tuncer ZS. The evaluation of laparotomy results in breast cancer patients with gynecological pathologies. Journal of Obstetrics and Gynaecology Research. 2020 Oct 10;46(10):2126–33. Jeon J, Kim SE, Lee DY, Choi D. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Res Treat. 2020 Jan 20;179(1):125–30. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004 Aug;94(2):256–66. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The Oncogenic Potential of Endometrial Polyps. Obstetrics & Gynecology. 2010 Nov;116(5):1197–205. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *. JNCI: Journal of the National Cancer Institute. 1994 Apr 6;86(7):527–37. Romero SA, Young K, Hickey M, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews. 2020 Dec 21;2021(2). Feldman S, Shapter A, Welch WR, Berkowitz RS. Two-Year Follow-Up of 263 Patients with Post/Perimenopausal Vaginal Bleeding and Negative Initial Biopsy. Gynecol Oncol. 1994 Oct;55(1):56–9. F. Machado, J.R. Rodríguez(h), J.P.H. León, J.R. Rodríguez, J.J. Parrilla, L. Abad. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol . 2005;26(3):257–65. Committee Opinion No. 601. Obstetrics & Gynecology. 2014 Jun;123(6):1394–7. Guo J, Zhang Y, Qian H, Ma F, Cui X, Duan H. The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter? Arch Gynecol Obstet. 2019 Nov 1;300(5):1399–404. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. JNCI: Journal of the National Cancer Institute. 2018 Apr 1;110(4):354–61. Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat. 2015 Apr 13;150(2):439–45. Engin H. High-grade endometrial stromal sarcoma following tamoxifen treatment. Gynecol Oncol. 2008 Jan;108(1):253–4. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature. International Journal of Gynecological Cancer. 2002 Sep;12(5):496–500. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. International Journal of Gynecological Cancer. 2005 Nov;15(6):1239–42. Copyright (c) 2023 Sefa Kurt, Samican Ozmen, Onur Yavuz, Orkun Ilgen, Emine Cagnur Ulukus This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
- 1 December 2023
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 7 (12) , 754-759
Open AccessEndometrial pathologies in clinical follow-up of patients with hormone receptor-positive/negative breast cancer
Background/Aim: Breast cancer is the leading cause of cancer-related fatalities in women. Tamoxifen, a selective estrogen receptor modulator (SERM), is frequently employed for chemoprevention in hormone receptor (HR)-positive breast cancer patients due to its anti-estrogenic impact on breast tissue. Nevertheless, tamoxifen exhibits agonistic effects on the endometrium, particularly in postmenopausal women. This study aims to assess gynecological issues and endometrial pathologies that emerge during the treatment and follow-up phases of women diagnosed with HR-positive/negative breast cancer. Methods: This cohort study involved a data review from 857 breast cancer patients diagnosed over a decade at a tertiary center. Histopathological endometrial findings were evaluated for 166 patients who underwent gynecological consultations before breast cancer treatment with normal examination results and underwent invasive assessments due to gynecological symptoms that arose during treatment and follow-up. The study encompassed cases culminating in total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH+BSO). Results: The study analyzed 166 cases meeting the inclusion criteria. The mean age at breast cancer diagnosis was 48 years with a standard deviation of 8.4 years, and the average follow-up duration was 4.1 (3.8) years. The predominant histopathological type was invasive ductal carcinoma (75.3%). Of the cases, 68.6% occurred during premenopausal and 31.4% during postmenopause. HR positivity was identified in 136 cases (81.9%), while 30 (18.1%) exhibited negative HR status. Among HR-positive cases, 113 (83.0%) received tamoxifen treatment, while 23 (17.0%) were treated with letrozole. Common clinical findings during and after treatment encompassed increased endometrial thickness (ET) and abnormal uterine bleeding (AUB). Histopathological evaluation of invasive procedures prompted by increased ET indicated the following frequent endometrial findings: proliferative endometrium (33.1%), endometrial polyp (20.5%), and endometrial hyperplasia (EH) without atypia (9%). The histopathological outcomes of invasive procedures prompted by AUB included atrophic endometrium (11.4%), proliferative endometrium (3.6%), and endometrial cancer (1.8%). Among the endometrial malignancies, three occurred in the premenopausal phase and four in the postmenopausal phase. Notably, three of the seven endometrial malignancies were observed in the tamoxifen hormone therapy group, all HR-positive. Four cases were from the non-tamoxifen hormone therapy group with negative HR status. Conclusion: Globally, breast cancer ranks as the most prevalent malignancy in women. Tamoxifen, a frequently utilized adjuvant therapy post breast cancer surgery, can exert diverse effects on gynecological organs, encompassing benign pathologies like increased ET and malignant pathologies like uterine neoplasia. There is a rising suspicion that etiopathogenetic factors contributing to breast cancer progression might also precipitate uterine cancer, irrespective of tamoxifen use. Vigilant patient monitoring is paramount for detecting uterine neoplasia and other gynecological pathologies. '+st+' Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May 4;71(3):209–49. Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012 Apr 26;344(apr26 1):e2718–e2718. Jordan VC. The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Ann Surg Oncol. 2019 Jul 25;26(7):1981–90. Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020 Sep 7;12(9):2535. Fleming CA, Heneghan HM, O’Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. British Journal of Surgery. 2018 Jul 11;105(9):1098–106. Freeman EW, Sammel MD, Gracia CR, Kapoor S, Lin H, Liu L, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril. 2005 Feb;83(2):383–92. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022 Nov 3;72(6):524–41. Yin L, Duan JJ, Bian XW, Yu S cang. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research. 2020 Dec 9;22(1):61. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of Endometrial Changes among Symptomatic Tamoxifen-Treated and Nontreated Premenopausal and Postmenopausal Breast Cancer Patients. Gynecol Oncol. 1997 Aug;66(2):233–7. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJD, Cordoba M, et al. Time-Dependent Effect of Tamoxifen Therapy on Endometrial Pathology in Asymptomatic Postmenopausal Breast Cancer Patients. International Journal of Gynecological Pathology. 1996 Apr;15(2):152–7. Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, et al. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-535.e5. Şahin Uysal N, Boyraz G, Usubütün A, Tuncer ZS. The evaluation of laparotomy results in breast cancer patients with gynecological pathologies. Journal of Obstetrics and Gynaecology Research. 2020 Oct 10;46(10):2126–33. Jeon J, Kim SE, Lee DY, Choi D. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Res Treat. 2020 Jan 20;179(1):125–30. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004 Aug;94(2):256–66. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The Oncogenic Potential of Endometrial Polyps. Obstetrics & Gynecology. 2010 Nov;116(5):1197–205. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *. JNCI: Journal of the National Cancer Institute. 1994 Apr 6;86(7):527–37. Romero SA, Young K, Hickey M, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews. 2020 Dec 21;2021(2). Feldman S, Shapter A, Welch WR, Berkowitz RS. Two-Year Follow-Up of 263 Patients with Post/Perimenopausal Vaginal Bleeding and Negative Initial Biopsy. Gynecol Oncol. 1994 Oct;55(1):56–9. F. Machado, J.R. Rodríguez(h), J.P.H. León, J.R. Rodríguez, J.J. Parrilla, L. Abad. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol . 2005;26(3):257–65. Committee Opinion No. 601. Obstetrics & Gynecology. 2014 Jun;123(6):1394–7. Guo J, Zhang Y, Qian H, Ma F, Cui X, Duan H. The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter? Arch Gynecol Obstet. 2019 Nov 1;300(5):1399–404. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. JNCI: Journal of the National Cancer Institute. 2018 Apr 1;110(4):354–61. Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat. 2015 Apr 13;150(2):439–45. Engin H. High-grade endometrial stromal sarcoma following tamoxifen treatment. Gynecol Oncol. 2008 Jan;108(1):253–4. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature. International Journal of Gynecological Cancer. 2002 Sep;12(5):496–500. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. International Journal of Gynecological Cancer. 2005 Nov;15(6):1239–42. Copyright (c) 2023 Sefa Kurt, Samican Ozmen, Onur Yavuz, Orkun Ilgen, Emine Cagnur Ulukus This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.